

Clinical Trial Protocol

Iranian Registry of Clinical Trials

30 May 2026

Considering the administration of Desferal supplementary and Vitamin C on the ferritin levels of Quid 19 patients

Protocol summary

Study aim

The aim of this study was to assist with desferal drug and vitamin C in reducing iron overload caused by COVID-19 viral infection.

Design

In this study, the intervention, which is done as a randomized clinical trial, selected 78 patients with covid 19 virus who were randomly assigned to two groups with the treatment of desferal supplement with vitamin c and without the treatment of desferal and vitamin C. will be considered. C-reactive protein (CRP) ferritin levels were compared between the two groups using chi-square and Fisher tests and the significance level was 0.05.

Settings and conduct

People with COVID 19 are referred to the Corona ward in Shohada Tajrish Hospital and are treated with desferal supplement along with vitamin C.

Participants/Inclusion and exclusion criteria

The entry criteria for COVID 19 viral infection are high serum ferritin levels and an increase in inflammatory factors in the blood, and the criteria for leaving the study include patients with renal insufficiency or the use of desferal contraceptives.

Intervention groups

Interfering with the treatment of desferal deodorant Baduz 20 to 60 mg per kilogram of body weight with 100 mg of vitamin C and then serum ferritin and factor (C-reactive protein (CRP) which was initially taken from the patient again On the third day after the intervention, it is measured and in the patient control group, do not receive desferal supplement medication, and then at the end, the study of these two groups in terms of ferritin and CRP are compared.

Main outcome variables

The effect of desferal supplement with vitamin C on blood ferritin levels in covid 19 patients Effect of desferal supplement with vitamin C on C-reactive protein content in patients with covid 19

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20190121042444N3**

Registration date: **2020-07-04, 1399/04/14**

Registration timing: **registered_while_recruiting**

Last update: **2020-07-04, 1399/04/14**

Update count: **0**

Registration date

2020-07-04, 1399/04/14

Registrant information

Name

faranak behnaz

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 2274 1174

Email address

faranak.behnaz@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-02-20, 1398/12/01

Expected recruitment end date

2021-02-19, 1399/12/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Considering the administration of Desferal supplementary and Vitamin C on the ferritin levels of Quid 19 patients

Public title

Considering the administration of Desferal supplementary and Vitamin C on the ferritin levels of Quid 19 patients

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Get infected with a viral infection COVID-19 High serum ferritin levels Increased inflammatory factor in the blood

Exclusion criteria:

Patients with renal insufficiency Consumption of desferal supplementary in them is contraindicated

Age

No age limit

Gender

Both

Phase

3

Groups that have been masked

- Investigator
- Outcome assessor

Sample size

Target sample size: **78**

Randomization (investigator's opinion)

Randomized

Randomization description

In this method, based on the table of random numbers, first the number of samples is entered using a computer and each two-digit code is assigned. The researcher randomly selects a point in the Weston line. This table selects a point if the desired number is smaller than the sample size. Work continues until the sample size is complete

Blinding (investigator's opinion)

Single blinded

Blinding description

In this study, desferal supplement medication is taken by nurse . Here, nurse knows the type of complementary medicine. So the researcher is blind here

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Shahid Behesti University of

Medical Sciences

Street address

Yaman Ave,Velenjak

City

Tehran

Province

Tehran

Postal code

1467664961

Approval date

2020-06-23, 1399/04/03

Ethics committee reference number

IR.SBMU.RETECH.REC.1399.256

Health conditions studied

1

Description of health condition studied

COVID-19

ICD-10 code

U07.1

ICD-10 code description

U07.1 COVID positive

Primary outcomes

1

Description

CRP rate

Timepoint

Before the start of the intervention and the third day after the intervention

Method of measurement

Based on serum surface measurement

2

Description

CRP rate

Timepoint

Before the start of the intervention and the third day after the intervention

Method of measurement

Based on serum surface measurement

Secondary outcomes

empty

Intervention groups

1

Description

In this study, randomly placed in a group of patients with desferal supplementation at a dose of 20 to 60 mg by weight over 8 to 12 hours, along with 100 mg of vitamin C ampoules at the time of hospitalization in the corona section, followed by ferritin and CRP by The patient's blood test is checked to compare their differences with

before the intervention

Category

Treatment - Drugs

2

Description

In the control group, desferal supplementation is not given at a dose of 20 to 60 mg per kg body weight with 100 mg of vitamin C ampoules, and ferritin and CRP tests are sent to the patient. They are also compared

Category

N/A

Recruitment centers

1

Recruitment center

Name of recruitment center

Shphada Tajrish Hospital

Full name of responsible person

Faranak Behnaz

Street address

Shohada Hospital,Tajrish SQ ,Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1985711151

Phone

+98 21 2274 1174

Email

faranak.behnaz@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Nahid Asadi

Street address

Yaman AVE, Velenjak

City

Tehran

Province

Tehran

Postal code

1467664961

Phone

+98 21 2243 2572

Email

nahidasadi@yahoo.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shahid Beheshti University of Medical Sciences

Proportion provided by this source

30

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Faranak Behnaz

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Anesthesiology

Street address

Shohada Hospital, Tajrish SQ, Tehran , Iran

City

Tehran

Province

Tehran

Postal code

1985711151

Phone

+98 21 2274 1174

Email

faranak.behnaz@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Seyed Ebrahim Sadeghzadeh Sadat

Position

Rezident

Latest degree

Medical doctor

Other areas of specialty/work

Anesthesiology

Street address

Shohada Hospital,Tajrish SQ

City

Tehran

Province

Tehran

Postal code

1985711151

Phone

+98 21 2274 1174

Email

sadat13584@gmail.com

Person responsible for updating data**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Faranak Behnaz

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Anesthesiology

Street address

Shohada Hospital, Tajrish SQ

City

Tehran

Province

Tehran

Postal code

1985711151

Phone

+98 21 2274 1174

Email

faranak.behnaz@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Only part of the data, such as information about the main consequence or the like, can be shared.

When the data will become available and for how long

Start of access period from 1400

To whom data/document is available

Only for researchers in academic and scientific institutions

Under which criteria data/document could be used

Only data analysis is possible

From where data/document is obtainable

Dr. Faranak Behnaz, Address: Tehran, Tajrish Square, Shohada Experience Hospital, Tel: 0098212271174

What processes are involved for a request to access data/document

After submitting the application, a maximum of one week will be answered

Comments